Tekmira Provides Corporate Update and Announces 2011 Results
27 mars 2012 16h01 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
26 mars 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 26, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2011 Audited Results
22 mars 2012 16h40 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
22 mars 2012 01h17 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed...
Tekmira Provides Update on Progress in USPTO Patent Interference Proceedings
15 mars 2012 00h50 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 15, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Tekmira Files Motion to Dismiss in Patent Infringement Suit
06 mars 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 6, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Tekmira Expands Product Pipeline With RNAi Therapeutic for the Treatment of Alcohol Dependence
01 mars 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 1, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Updates Financial Guidance: Cash Runway Further Extended Into Second Half of 2013
29 févr. 2012 23h57 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, has updated its...
Tekmira Announces USPTO Issuance of Key Patents Broadly Covering LNP Formulations and Mitigation of Immune Stimulation
09 févr. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that the...
Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical Trial
08 févr. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...